亚洲知识产权资讯网为知识产权业界提供一个一站式网上交易平台，协助业界发掘知识产权贸易商机，并与环球知识产权业界建立联系。无论你是知识产权拥有者正在出售您的知识产权，或是制造商需要购买技术以提高操作效能，又或是知识产权配套服务供应商，你将会从本网站发掘到有用的知识产权贸易资讯。

返回搜索结果

Diagnostic Test for Cancer Susceptibility

详细技术说明

Researchers at the University of California have discovered a novel tumor suppressor gene, CDK4I, that inhibits the activity of the oncogene CDK4. The CDK4I gene is mutated in the majority of malignant melanomas, gliomas, non-small cell lung cancers, and leukemias. CDK4I is located immediately adjacent to the methylthioadenosine phosphorylase (MTAse) gene, on chromosome 9p21. Deficiencies in CDK4I and MTAse have previously been shown to be directly related to the onset of certain cancers. One of the U.S. patent applications that is available for licensing was involved in two interference proceedings with two parties before the U.S.P.T.O. The Regents of the University of California won the proceedings on the claims involved in both interferences. The Regents believes that these claims are not dominated by the U.S. patent claims of the other party to the interferences. However, any party must obtain its own opinion of counsel regarding the extent of issued claim coverage. The technology comprises diagnostic methods to detect mutations of the CDK4I gene as well as detecting deficiencies in the expression products of the gene. In addition, the technology also provides for the detection of mutations and altered gene product of the CDK4I-linked gene MTAse. The technique can be used to diagnose individuals who carry mutations in CDK4I or MTAse genes, and are therefore more susceptible to developing malignant melanoma and certain other familial and environmental cancers. Successful early detection of a pre-cancerous condition can enable effective measures to be taken to prevent subsequent cancer progression. The methods can also be applied to the screening and identification of anti-cancer molecules that will target aberrant CDK4I and MTAse gene products. In addition, these discoveries will be applied to research in the field of cell cycle regulation. While there have been significant advances in cancer therapies of late, early detection and subsequent treatment greatly increases the survival rate. The prevalence of mutations in the CDK4I gene in malignant cells makes it an important diagnostic target for early detection of cancer susceptibility. The procedures allow for the rapid analysis of CDK4I and MTAse gene and gene products for detection of mutations that may lead to uncontrolled cell proliferation and subsequent cancer progression.

附加资料

Patent Number: US6689561B1
Application Number: US1994227800A
Inventor: Carson, Dennis A. | Nobori, Tsutomu
Priority Date: 14 Apr 1994
Priority Number: US6689561B1
Application Date: 14 Apr 1994
Publication Date: 10 Feb 2004
IPC Current: C12N001509 | A61K003800 | A61P003500 | C07H002104 | C07K001447 | C07K001482 | C07K001618 | C07K001632 | C12P002102 | C12P002108 | C12Q000102 | C12Q000168 | G01N003353
US Class: 43500614 | 435006 | 4350912 | 435194 | 4353201 | 435325 | 5360231 | 53602433
Assignee Applicant: The Regents of the University of California
Title: Tumor suppressor gene and methods for detection of cancer, monitoring of tumor progression and cancer treatment
Usefulness: Tumor suppressor gene and methods for detection of cancer, monitoring of tumor progression and cancer treatment
Novelty: Cyclin dependent kinase inhibitor gene, related vectors and antibodies useful for diagnosis, assessing predisposition and treatment of cancers